Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kin Sing Stephen Lee has a total of 325 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A 96-well Platform for Maintaining Age-Synchronized Caenorhabditis elegans Populations Without Chemical or Genetic Intervention

    by Fatemeh Yousefsaber, Morteza Sarparast, Brian Johnson, Jamie K Alan, Kin Sing Stephen Lee

    Caenorhabditis elegans (C. elegans) is a well-established model for investigating the mechanisms of aging and age-related disorders. However, maintaining age-synchronized populations of C. elegans without genetic or pharmacological interventions presents significant challenges, given their high reproductive rate. The traditional method for maintaining an age-synchronized population for multi-day studies without interventions is labor-intensive and low-throughput. To address these limitations, a novel method was developed to sustain age-synchronized populations in a 96-well plate liquid culture format for up to 12 days without custom-made apparatuses. The feasibility of this method was substantially improved by optimizing the surface composition of the multi-well plate and disposables and refining culture parameters. To facilitate unbiased phenotype assessment throughout the lifespan, we used a Wmicrotracker ONE reader to monitor worm movement and viability. The overall fitness decline with aging using our method is comparable to that of worms maintained on solid culture. Lastly, using transgenic C. elegans carrying tauopathy, we demonstrated that our optimized platform yields a Z-factor in the range of 0.65–0.68 at Day 3 and Day 5 adult worms, which is well above commonly used quality thresholds for multi-well screening assays. Our method simplifies age-synchronized population maintenance, enhances progeny separation, and reduces per-assay consumable costs by reusing mesh filters and batch-treated labware, enabling screening of compounds and RNAi libraries. These advancements greatly enhance the versatility of C. elegans as a model organism, offering a scalable platform for genetic and compound screening and for comprehensive investigations into drug discovery and disease mechanisms.

  • Open Access

    A Robust Chemical-free Platform for Age-Synchronized Caenorhabditis elegans Populations Maintenance for High-Throughput Screening in Aging Studies

    by Fatemeh Yousefsaber, Morteza Sarparast, Brian Johnson, Jamie Alan, Kin Sing Stephen Lee

    Caenorhabditis elegans ( C. elegans ) is a well-established model for investigating the mechanisms of aging and age-related disorders like neurodegeneration. However, maintaining age-synchronized populations of C. elegans for aging studies without genetic or pharmacological interventions presents significant challenges, given their high reproductive rate: each nematode produces over 300 progeny. The traditional method for maintaining an age-synchronized population for multi-day studies without interventions is labor-intensive and low-throughput, hindering research on aging mechanisms and the identification of novel interventions for aging. To address these limitations, a novel, robust method was developed to sustain age-synchronized populations in a 96-well plate liquid culture format for up to 12 days without custom-made apparatuses. The robustness of this method was substantially improved by optimizing the surface composition of the multi-well plate and disposables, refining culture parameters, including life stage, medium composition, and bacterial food concentration. To facilitate unbiased phenotype assessment throughout the lifespan, we used a Wmicrotracker ONE reader to monitor worm movement and viability in a multi-well plate. The overall fitness decline with aging using our method is comparable to that of worms maintained on solid agar. Lastly, using transgenic C. elegans carrying tauopathy, we demonstrated the ability of applying our optimized platform for high-throughput screening with a Z-factor of 0.7. Our novel method simplifies age-synchronized population maintenance, enhances progeny separation, and reduces costs, enabling high-throughput screening of compounds and RNAi libraries. These advancements greatly enhance the versatility of C. elegans as a model organism, offering a scalable platform for genetic and compound screening and for comprehensive investigations into drug discovery and disease mechanisms.

  • Open Access

    Effects of molecular interactions between the exposome and oxylipin metabolism on healthspan

    by Jennifer Hinman, Jamie K. Alan, Kin Sing Stephen Lee

    While aging is typically synonymous with the lifespan of an individual, the healthspan, or the total number of years an individual remains healthy and disease-free, is not necessarily related. A current, critical need in society has arisen as current populations are living longer than previous generations, thus increasing the number of people with age-associated diseases. However, the extent of all age mechanisms is not entirely known. Still, studies examining how the exposome, or an individual’s cumulative exposures throughout their life, can influence or modulate aging processes will strengthen our understanding of how to keep individuals healthy and disease-free longer, bridging the gap between lifespan and healthspan. In contrast, previous research has also demonstrated that the exposome impacts aging. One subcategory of the exposome, the specific external, encompasses daily exposures such as diet, lifestyle factors, and occupational and environmental exposures. In this review, we focus on the interactions between factors of the exposome, such as vitamins and minerals, and their effects on aging, cell death, cellular senescence, and unsaturated fatty acid metabolism. We also discuss the interaction between oxidative fatty acid metabolism and aging itself. Overall, understanding how various exposures impact both the oxylipin profile and healthy aging will inform future interventions aimed at improving the healthspan and quality of life for this large aging population.


  • Open Access

    Effects of 17,18-Epoxyeicosatetraenoic Acid and 19,20-Epoxydocosapentaenoic Acid Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Brown Adipogenesis and Mitochondrial Respiration

    by Yang Yang, Haoying Wu, Xinyun Xu, Christophe Morisseau, Kin Sing Stephen Lee, Bruce D. Hammock, Jiangang Chen, Ling Zhao

    Background/Objectives: 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP) are bioactive metabolites produced from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, by CYP450s. These metabolites are unstable and quickly metabolized by auto-oxidation, esterification, β-oxidation, or hydrolysis by soluble epoxide hydrolase (sEH). 17,18-EEQ or 19,20-EDP combined with a potent sEH inhibitor t-TUCB differentially activated brown adipose tissue in diet-induced obesity. In the current study, we investigated whether these n-3 epoxy fatty acids with t-TUCB directly promote brown adipocyte differentiation and their thermogenic capacities. Methods: Murine brown preadipocytes were treated with 17,18-EEQ or 19,20-EDP with t-TUCB during and post differentiation. Brown marker protein expression and mitochondrial respiration were measured. In addition, the activation of PPARγ and suppression of NFκB reporter by 17,18-EEQ or 19,20-EDP alone or with t-TUCB were assessed, and the roles of PPARγ were evaluated with PPARγ knockdown and GW9662. Results: 17,18-EEQ or 19,20-EDP with t-TUCB promoted brown adipogenesis and mitochondrial respiration and uncoupling. Moreover, with t-TUCB, both epoxides improved mitochondrial respiration, but only 17,18-EEQ with t-TUCB significantly increased mitochondrial uncoupling (and heat production) in the differentiated adipocytes. PPARγ may be required for the effects of epoxides on differentiation but not on the thermogenic function post differentiation. Conclusions: The results demonstrate that, with t-TUCB, 17,18-EEQ and 19,20-EDP promote brown adipogenesis and mitochondrial respiration and uncoupling. 17,18-EEQ also promotes thermogenesis in differentiated brown adipocytes. Together, the results suggest thermogenic potentials of tested n-3 epoxides, especially 17,18-EEQ with t-TUCB. Translational studies of these n-3 epoxides on human brown adipocyte differentiation and functions are warranted.


  • Open Access

    Quantitative Profiling Method for Oxylipins in Neurodegenerative Diseases by Liquid Chromatography Coupled with Tandem Mass Spectrometry

    by Elham Pourmand, Fan Zhang, Morteza Sarparast, Jamie K. Alan, Kin Sing Stephen Lee

    Aging is one of the major risk factors for many chronic diseases, including diabetes, neuropathy, hypertension, cancer, and neurodegenerative diseases. However, the mechanism behind aging and how aging affects a variety of disease progression remains unknown. Recent research demonstrated the cytochrome P450 (CYP)-epoxide hydrolase (EH) metabolites of polyunsaturated fatty acids (PUFAs) play a critical role in the abovementioned age-associated diseases. Therefore, aging could affect the abovementioned chronic diseases by modulating CYP-EH PUFA metabolism. Unfortunately, investigating how aging affects CYP-EH metabolism in human and mammalian models poses significant challenges. In this regard, we will use C. elegans as a model organism to investigate the aging effects on CYP-EH metabolism of PUFA, owing to its long history of being used to study aging and its associated benefits of conducting aging research. This project will develop analytical tools to measure the endogenous levels of CYP-EH PUFA metabolites in C. elegans using state-of-the-art ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). These metabolites are very potent but present in low abundance. The dramatic increase in sensitivity in UPLC-MS/MS allows us to monitor these metabolites over the lifespan of C. elegans with minimum samples. Our results show that C. elegans produces similar CYP PUFA metabolites to mammals and humans using our SPE-UPLC-MS/MS method. We will also show that our method successfully determined the CYP-EH PUFA metabolites profile changes induced by the inhibition of C. elegans EH. The method developed from this project will significantly improve our understanding of the role of dietary PUFAs and associated metabolism on aging and neurodegeneration and will uncover new mechanisms of how aging affects neurodegeneration through the modulation of PUFA metabolic pathways. Graphical

  • Open Access

    Cytochrome P450 and Epoxide Hydrolase Metabolites in Aβ and tau-induced Neurodegeneration: Insights from Caenorhabditis elegans

    by Morteza Sarparast, Jennifer Hinman, Elham Pourmand, Derek Vonarx, Leslie Ramirez, Wenjuan Ma, Nicole F. Liachko, Jamie K. Alan, Kin Sing Stephen Lee

    This study aims to uncover potent cytochrome P450 (CYP) and epoxide hydrolase (EH) metabolites implicated in Aβ and/or tau-induced neurodegeneration, independent of neuroinflammation, by utilizing Caenorhabditis elegans ( C. elegans ) as a model organism. Our research reveals that Aβ and/or tau expression in C. elegans disrupts the oxylipin profile, and epoxide hydrolase inhibition alleviates the ensuing neurodegeneration, likely through elevating the epoxy-to-hydroxy ratio of various CYP-EH metabolites. In addition, our results indicated that the Aβ and tau likely affect the CYP-EH metabolism of PUFA through different mechanism. These findings emphasize the intriguing relationship between lipid metabolites and neurodegenerations, in particular, those linked to Aβ and/or tau aggregation. Furthermore, our investigation sheds light on the crucial and captivating role of CYP PUFA metabolites in C. elegans physiology, opening up possibilities for broader implications in mammalian and human contexts. Abstract Figure:


  • Open Access

    How robust is the ligand binding transition state?

    by Samik Bose, Samuel Lotz, Indrajit Deb, Megan Shuck, Kin Sing Stephen Lee, Alex Dickson

    For many drug targets, it has been shown that the kinetics of drug binding (e.g. on rate and off rate) is more predictive of drug efficacy than thermodynamic quantities alone. This motivates the development of predictive computational models that can be used to optimize compounds on the basis of their kinetics. The structural details underpinning these computational models are not only found in the bound state, but also in the short-lived ligand binding transition state: the highest free energy point along the (un)binding pathway. Although this transition state cannot be directly observed experimentally, due to its extremely short lifetime, recent successes have demonstrated that modeling of the ligand binding transition state is possible with the help of enhanced sampling methods for molecular dynamics. In our previous work we analyzed the transition state ensemble for an inhibitor of soluble epoxide hydrolase (sEH) with a residence time of 11 minutes. Here we computationally modeled unbinding events for five additional inhibitors of sEH with residence times ranging from 14.25 to 31.75 minutes, with our results recapitulating these experimental residence times to within an order of magnitude. The unbinding ensembles are analyzed in detail, focusing on features of the ligand binding transition state. We find that ligands with similar structures and similar bound poses can show significant differences in their ligand binding transition states, in terms of their spatial location and their interactions with specific protein residues. However we also find similarities across the transition state ensembles when examining more general features such as ligand degrees of freedom. Together these findings show significant challenges for rational, kinetics-based drug design.

  • Open Access

    Supplementary Figure S1-S7 from Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis

    by Weicang Wang, Jun Yang, Matthew L. Edin, Yuxin Wang, Ying Luo, Debin Wan, Haixia Yang, Chun-Qing Song, Wen Xue, Katherine Z. Sanidad, et al.

    SF1: CYP monooxygenase expression in human colon cancer cells; SF2: gene expression of Cyp2e1 in the liver of Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF3: liver inflammation in Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF4: survival curve of the AOM/DSS-stimulated Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF5: pharmacological inhibition of CYP monooxygenases suppresses AOM/DSS-induced colon tumorigenesis in mice; SF6: effects of 12,13-EpOME on MC38 tumor growth in C57BL/6 mice; SF7: mRNA expression levels of CYP monooxygenases in control subjects and colon cancer patients

  • Open Access

    Supplementary Figure S1-S7 from Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis

    by Weicang Wang, Jun Yang, Matthew L. Edin, Yuxin Wang, Ying Luo, Debin Wan, Haixia Yang, Chun-Qing Song, Wen Xue, Katherine Z. Sanidad, et al.

    SF1: CYP monooxygenase expression in human colon cancer cells; SF2: gene expression of Cyp2e1 in the liver of Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF3: liver inflammation in Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF4: survival curve of the AOM/DSS-stimulated Cyp2c+/+, Cyp2c+/-, and Cyp2c-/- mice; SF5: pharmacological inhibition of CYP monooxygenases suppresses AOM/DSS-induced colon tumorigenesis in mice; SF6: effects of 12,13-EpOME on MC38 tumor growth in C57BL/6 mice; SF7: mRNA expression levels of CYP monooxygenases in control subjects and colon cancer patients

  • Open Access

    Supplementary Table S1-S5 from Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis

    by Weicang Wang, Jun Yang, Matthew L. Edin, Yuxin Wang, Ying Luo, Debin Wan, Haixia Yang, Chun-Qing Song, Wen Xue, Katherine Z. Sanidad, et al.

    ST1: Composition of the modified AIN-93G diet used in the animal experiment; ST2: Sequences of primers in qRT-PCR; ST3: Concentrations of lipid mediators in the plasma of control mice (not treated with AOM/DSS) and colon cancer mice (treated with AOM/DSS); ST4: Concentrations of lipid mediators in the colon of control mice (not treated with AOM/DSS) and colon cancer mice (treated with AOM/DSS); ST5: Concentrations of lipid mediators in the colon of AOM/DSS-treated Cyp2c+/+ and Cyp2c+/- mice.